
BreezeBio Secures $60M Series B to Advance Genetic Medicines for Autoimmune Diseases
Funding Boosts Development of NanoGalaxy Platform and Lead Candidate BRZ-101 for Type 1 Diabetes Why is targeted gene delivery a critical challenge in the biotech industry? BreezeBio, a biotechnology company headquartered in South San Francisco, is addressing this issue with…












